Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture

Julia Macharey

Photograph of Julia Macharey standing up and looking into the camera.

ORION CORPORATION
STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS
22 August 2023 at 14.00 EEST             
        

Change in Orion Group Executive Management Board as of February 1st, 2024Julia Macharey appointed Senior Vice President, People & Culture

Ms. Julia Macharey has been appointed Senior Vice President of Orion Group’s new People & Culture group-level function and member of the Executive Management Board of Orion Group as of February 1st 2024. She will report to President & CEO Liisa Hurme. She currently holds the position of Senior Vice President, Human Resources and Operational Development at Valmet and is a member of the Valmet Executive Team. Julia Macharey holds a Master of Science degree in Economics and a Bachelor of Arts degree.

“With this appointment, I wanted to support the implementation of our global growth strategy and to strengthen the building of Orion’s corporate culture. Based on her previous experience and track record, Julia Macharey will bring both global organizational and business perspective to Orion,” says Orion’s President & CEO Liisa Hurme.

“I am very excited about the opportunity of joining a team of world-class experts who endeavor to improve well-being through life-saving and life-improving medicines and treatments. Orion’s people-oriented culture based on working together to create high-quality products is only one of the many reasons why I am looking forward to supporting Orion on its growth path,” says Julia Macharey about the appointment.

The new People & Culture function will focus on developing Orion’s professionals, capabilities and company culture and supporting growth, and Human Resources will be at the heart of this new group-level function as of February 1st.

“Orion’s organisation has seen significant geographical expansion in recent years, and we want to continue developing our people and culture in a global and systematic way. I am excited about the new opportunities in this and I warmly welcome Julia to Orion and to our management team,” says Liisa Hurme.

ANNEX: CV of Julia Macharey

Julia Macharey
Born 1977
Finnish citizen

Education:

Master of Science in Economics, University of Jyväskylä, 2000
Bachelor of Arts (Intercultural Communication), University of Jyväskylä, 1999

Career:

Valmet

2019–              Senior Vice President, Human Resources and Operational Development
2014–2019        Senior Vice President, Human Resources

Metso Corporation, Metso Paper
2012–2013        Senior Vice President, Human Resources of Metso Pulp, Paper and Power segment

Pöyry Plc        
2007–2012        Vice President, Human Resources of Industry Business Group

Nokia Corporation
2006–2007        Senior Manager, Business HR of Manufacturing Solutions
2004–2006        Senior Manager, Business HR of Sourcing and Procurement

SCA Hygiene Products Ltd and GmbH
2000–2004        Human Resources Manager and various HR management responsibilities

Attachment:

Orion Corporation

Liisa Hurme

President and CEO

    Olli Huotari

SVP, Corporate Functions

 

                                                
Contact person:
Liisa Hurme, President and CEO
tel. +358 50 966 2874, liisa.hurme@orion.fi

Contact person for the media:
Terhi Ormio, VP, Communications
tel. + 358 50 966 4646, terhi.ormio@orion.fi

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion’s net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

 

Attachment

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

24 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

25 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

28 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

28 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

28 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

28 minutes ago